Back to Search Start Over

Communicating regulatory high-throughput sequencing data using BioCompute Objects.

Authors :
King CHS 4th
Keeney J
Guimera N
Das S
Weber M
Fochtman B
Walderhaug MO
Talwar S
Patel JA
Mazumder R
Donaldson EF
Source :
Drug discovery today [Drug Discov Today] 2022 Apr; Vol. 27 (4), pp. 1108-1114. Date of Electronic Publication: 2022 Jan 22.
Publication Year :
2022

Abstract

This project demonstrates the use of the IEEE 2791-2020 Standard (BioCompute Objects [BCO]) to enable the complete and concise communication of results from next generation sequencing (NGS) analysis. One arm of a clinical trial was replicated using synthetically generated data made to resemble real biological data and then two independent analyses were performed. The first simulated a pharmaceutical regulatory submission to the US Food and Drug Administration (FDA) including analysis of results and a BCO. The second simulated an FDA review that included an independent analysis of the submitted data. Of the 118 simulated patient samples generated, 117 (99.15%) were in agreement in the two analyses. This process exemplifies how a template BCO (tBCO), including a verification kit, facilitates transparency and reproducibility, thereby reinforcing confidence in the regulatory submission process.<br /> (Copyright © 2022. Published by Elsevier Ltd.)

Details

Language :
English
ISSN :
1878-5832
Volume :
27
Issue :
4
Database :
MEDLINE
Journal :
Drug discovery today
Publication Type :
Academic Journal
Accession number :
35077912
Full Text :
https://doi.org/10.1016/j.drudis.2022.01.007